<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872311</url>
  </required_header>
  <id_info>
    <org_study_id>MCL10416</org_study_id>
    <nct_id>NCT02872311</nct_id>
  </id_info>
  <brief_title>Open-Label Influenza Vaccine Evaluation</brief_title>
  <acronym>OLIVE</acronym>
  <official_title>Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshfield Clinic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Marshfield Clinic Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the
      immune response to consecutive influenza vaccination across 2 seasons. Participants will be
      randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will
      receive the same vaccination in the second year and the third arm will be randomized again to
      1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood
      draws for a total of 6 draws over 18 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination</measure>
    <time_frame>Year 1, Day 28 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination</measure>
    <time_frame>Year 1, Day 182 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination</measure>
    <time_frame>Year 1, Day 365 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination</measure>
    <time_frame>Year 2, Day 28 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination</measure>
    <time_frame>Year 2, Day 182 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination</measure>
    <time_frame>Year 1, Day 28 post vaccination</time_frame>
    <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 28 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination</measure>
    <time_frame>Year 1, Day 182 post vaccination</time_frame>
    <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 182 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination</measure>
    <time_frame>Year 1, Day 365 post vaccination</time_frame>
    <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 365 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination</measure>
    <time_frame>Year 1, Day 28 post vaccination</time_frame>
    <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination</measure>
    <time_frame>Year 1, Day 182 post vaccination</time_frame>
    <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 182 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination</measure>
    <time_frame>Year 1, Day 365 post vaccination</time_frame>
    <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 365 days post vaccination, 2016-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination</measure>
    <time_frame>Year 2, Day 28 post vaccination</time_frame>
    <description>Microneutralization antibody titers to vaccine virus (A/Hong Kong (siat cell) among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2017-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination</measure>
    <time_frame>Year 2, Day 28 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 28 days post vaccination 2017-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination</measure>
    <time_frame>Year 2, Day 182 post vaccination</time_frame>
    <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 182 days post vaccination 2017-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination</measure>
    <time_frame>Year 2, Day 28 post vaccination</time_frame>
    <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 28 days after vaccination, 2017-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination</measure>
    <time_frame>Year 2, Day 182 post vaccination</time_frame>
    <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 182 days after vaccination, 2017-18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vaccine Failure, Year 1</measure>
    <time_frame>Year 1, Post season</time_frame>
    <description>Number of Participants with Vaccine Failure in Year 1 by vaccine type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vaccine Failure, Year 2</measure>
    <time_frame>Year 2, Post season</time_frame>
    <description>Number of Participants with Vaccine Failure in Year 2 by two-year vaccine history</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High Dose Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
    <arm_group_label>High Dose Influenza Vaccine</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <other_name>Fluzone HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
    <arm_group_label>Adjuvanted Influenza Vaccine</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <other_name>FluAd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard Dose Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
    <arm_group_label>Standard Dose Influenza Vaccine +Adj</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine+HD</arm_group_label>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <other_name>Fluvirin Standard Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Influenza vaccine</intervention_name>
    <description>Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
    <arm_group_label>Standard Dose Influenza Vaccine+Recomb</arm_group_label>
    <other_name>FluBlok</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 65-74 years at the time of study enrollment and are ambulatory and live in
             selected Wisconsin community or surrounding communities.

          -  Willing and able to give informed consent prior to study enrollment

          -  Able to comply with study requirements.

        Exclusion Criteria:

          -  Prior receipt of 2016-17 influenza vaccine

          -  Current participation in another clinical trial

          -  Presence of a contraindication to influenza vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <results_first_submitted>April 23, 2019</results_first_submitted>
  <results_first_submitted_qc>December 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marshfield Clinic Research Foundation</investigator_affiliation>
    <investigator_full_name>Huong McLean, PhD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Influenza</keyword>
  <keyword>High Dose</keyword>
  <keyword>Adjuvanted</keyword>
  <keyword>Recombinant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02872311/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Influenza Vaccine</title>
          <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
        </group>
        <group group_id="P2">
          <title>Adjuvanted Influenza Vaccine</title>
          <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
        </group>
        <group group_id="P3">
          <title>Standard+High Dose</title>
          <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and high dose influenza vaccination (0.5mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
        </group>
        <group group_id="P4">
          <title>Standard+Adjuvanted</title>
          <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
        </group>
        <group group_id="P5">
          <title>Standard+Recombinant</title>
          <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
Recombinant Influenza vaccine: Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Influenza Vaccine</title>
          <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
        </group>
        <group group_id="B2">
          <title>Adjuvanted Influenza Vaccine</title>
          <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
        </group>
        <group group_id="B3">
          <title>Standard Dose Influenza Vaccine+HD</title>
          <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
        </group>
        <group group_id="B4">
          <title>Standard Dose Influenza Vaccine +Adj</title>
          <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
        </group>
        <group group_id="B5">
          <title>Standard Dose Influenza Vaccine+Recomb</title>
          <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants
Recombinant Influenza vaccine: Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="2.7"/>
                    <measurement group_id="B2" value="69.6" spread="2.6"/>
                    <measurement group_id="B3" value="69.4" spread="2.9"/>
                    <measurement group_id="B4" value="69.2" spread="2.2"/>
                    <measurement group_id="B5" value="70" spread="2.7"/>
                    <measurement group_id="B6" value="70" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race : White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17</description>
        <time_frame>Year 1, Day 28 post vaccination</time_frame>
        <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17</description>
          <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="128" upper_limit="239"/>
                    <measurement group_id="O2" value="117" lower_limit="87" upper_limit="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="102" upper_limit="201"/>
                    <measurement group_id="O2" value="118" lower_limit="87" upper_limit="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="117" upper_limit="236"/>
                    <measurement group_id="O2" value="81" lower_limit="59" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17</description>
        <time_frame>Year 1, Day 182 post vaccination</time_frame>
        <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17</description>
          <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="62" upper_limit="110"/>
                    <measurement group_id="O2" value="56" lower_limit="41" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="60" upper_limit="113"/>
                    <measurement group_id="O2" value="68" lower_limit="51" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="43" upper_limit="88"/>
                    <measurement group_id="O2" value="44" lower_limit="33" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17</description>
        <time_frame>Year 1, Day 365 post vaccination</time_frame>
        <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17</description>
          <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="40" upper_limit="72"/>
                    <measurement group_id="O2" value="44" lower_limit="32" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="55" upper_limit="103"/>
                    <measurement group_id="O2" value="75" lower_limit="57" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="25" upper_limit="52"/>
                    <measurement group_id="O2" value="24" lower_limit="17" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18</description>
        <time_frame>Year 2, Day 28 post vaccination</time_frame>
        <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18</description>
          <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="64" upper_limit="107"/>
                    <measurement group_id="O2" value="101" lower_limit="74" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="114" upper_limit="220"/>
                    <measurement group_id="O2" value="158" lower_limit="123" upper_limit="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="46" upper_limit="87"/>
                    <measurement group_id="O2" value="45" lower_limit="33" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18</description>
        <time_frame>Year 2, Day 182 post vaccination</time_frame>
        <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18</description>
          <population>This primary objective evaluated only recipients in the arms receiving high dose and adjuvanted vaccine in year 1.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="35" upper_limit="61"/>
                    <measurement group_id="O2" value="44" lower_limit="32" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="74" upper_limit="138"/>
                    <measurement group_id="O2" value="124" lower_limit="93" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="31" upper_limit="61"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination</title>
        <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 28 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 28 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
        <group_list>
          <group group_id="O1">
            <title>IIV-ADJ</title>
            <description>2015-16 Standard dose vaccine recipient who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O2">
            <title>IIV-HD</title>
            <description>2015-16 Standard dose vaccine recipient who received high dose vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O3">
            <title>None-ADJ</title>
            <description>2015-16 Unvaccinated individual who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O4">
            <title>None-HD</title>
            <description>2015-16 Unvaccinated individual who received high dose vaccine in the study in 2016-17</description>
          </group>
        </group_list>
        <measure>
          <title>HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination</title>
          <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 28 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="82" upper_limit="165"/>
                    <measurement group_id="O2" value="136" lower_limit="95" upper_limit="193"/>
                    <measurement group_id="O3" value="122" lower_limit="62" upper_limit="241"/>
                    <measurement group_id="O4" value="343" lower_limit="194" upper_limit="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" lower_limit="76" upper_limit="147"/>
                    <measurement group_id="O2" value="128" lower_limit="85" upper_limit="193"/>
                    <measurement group_id="O3" value="168" lower_limit="82" upper_limit="343"/>
                    <measurement group_id="O4" value="197" lower_limit="106" upper_limit="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="45" upper_limit="84"/>
                    <measurement group_id="O2" value="142" lower_limit="93" upper_limit="217"/>
                    <measurement group_id="O3" value="195" lower_limit="87" upper_limit="435"/>
                    <measurement group_id="O4" value="254" lower_limit="136" upper_limit="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination</title>
        <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 182 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 182 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
        <group_list>
          <group group_id="O1">
            <title>IIV-ADJ</title>
            <description>2015-16 Standard dose vaccine recipient who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O2">
            <title>IIV-HD</title>
            <description>2015-16 Standard dose vaccine recipient who received high dose vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O3">
            <title>None-ADJ</title>
            <description>2015-16 Unvaccinated individual who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O4">
            <title>None-HD</title>
            <description>2015-16 Unvaccinated individual who received high dose vaccine in the study in 2016-17</description>
          </group>
        </group_list>
        <measure>
          <title>HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination</title>
          <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 182 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="41" upper_limit="85"/>
                    <measurement group_id="O2" value="67" lower_limit="49" upper_limit="91"/>
                    <measurement group_id="O3" value="48" lower_limit="23" upper_limit="98"/>
                    <measurement group_id="O4" value="146" lower_limit="81" upper_limit="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="49" upper_limit="96"/>
                    <measurement group_id="O2" value="84" lower_limit="56" upper_limit="126"/>
                    <measurement group_id="O3" value="67" lower_limit="35" upper_limit="128"/>
                    <measurement group_id="O4" value="78" lower_limit="47" upper_limit="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="27" upper_limit="48"/>
                    <measurement group_id="O2" value="51" lower_limit="33" upper_limit="77"/>
                    <measurement group_id="O3" value="86" lower_limit="38" upper_limit="196"/>
                    <measurement group_id="O4" value="103" lower_limit="52" upper_limit="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination</title>
        <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 365 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 365 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
        <group_list>
          <group group_id="O1">
            <title>IIV-ADJ</title>
            <description>2015-16 Standard dose vaccine recipient who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O2">
            <title>IIV-HD</title>
            <description>2015-16 Standard dose vaccine recipient who received high dose vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O3">
            <title>None-ADJ</title>
            <description>2015-16 Unvaccinated individual who received adjuvanted vaccine in the study in 2016-17</description>
          </group>
          <group group_id="O4">
            <title>None-HD</title>
            <description>2015-16 Unvaccinated individual who received high dose vaccine in the study in 2016-17</description>
          </group>
        </group_list>
        <measure>
          <title>HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination</title>
          <description>Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 365 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients by prior season vaccination status.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/California</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="36" upper_limit="74"/>
                    <measurement group_id="O2" value="48" lower_limit="34" upper_limit="67"/>
                    <measurement group_id="O3" value="26" lower_limit="13" upper_limit="52"/>
                    <measurement group_id="O4" value="73" lower_limit="39" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="59" upper_limit="114"/>
                    <measurement group_id="O2" value="79" lower_limit="53" upper_limit="117"/>
                    <measurement group_id="O3" value="58" lower_limit="31" upper_limit="107"/>
                    <measurement group_id="O4" value="66" lower_limit="38" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="28"/>
                    <measurement group_id="O2" value="34" lower_limit="22" upper_limit="52"/>
                    <measurement group_id="O3" value="38" lower_limit="17" upper_limit="86"/>
                    <measurement group_id="O4" value="44" lower_limit="20" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination</title>
        <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 28 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination</title>
          <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3/Hong Kong 4801 (egg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" lower_limit="175" upper_limit="373"/>
                    <measurement group_id="O2" value="246" lower_limit="160" upper_limit="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong 4801 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="42" upper_limit="79"/>
                    <measurement group_id="O2" value="69" lower_limit="49" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/NZ0783 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="33" upper_limit="66"/>
                    <measurement group_id="O2" value="52" lower_limit="37" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/OR19 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="22" upper_limit="46"/>
                    <measurement group_id="O2" value="39" lower_limit="27" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination</title>
        <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 182 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 182 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination</title>
          <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 182 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3/Hong Kong 4801 (egg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="91" upper_limit="208"/>
                    <measurement group_id="O2" value="132" lower_limit="89" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong 4801 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="33" upper_limit="60"/>
                    <measurement group_id="O2" value="42" lower_limit="30" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/NZ0783 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="22" upper_limit="40"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/OR19 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="33"/>
                    <measurement group_id="O2" value="25" lower_limit="18" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination</title>
        <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 365 days post vaccination, 2016-17</description>
        <time_frame>Year 1, Day 365 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination</title>
          <description>Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 365 days post vaccination, 2016-17</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients to vaccine and drifted viruses.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3/Hong Kong 4801 (egg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="91" upper_limit="207"/>
                    <measurement group_id="O2" value="132" lower_limit="89" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong 4801 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="33" upper_limit="60"/>
                    <measurement group_id="O2" value="55" lower_limit="51" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/NZ0783 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="22" upper_limit="40"/>
                    <measurement group_id="O2" value="30" lower_limit="22" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/OR19 (siat cell)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="18" upper_limit="33"/>
                    <measurement group_id="O2" value="25" lower_limit="18" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination</title>
        <description>Microneutralization antibody titers to vaccine virus (A/Hong Kong (siat cell) among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2017-18</description>
        <time_frame>Year 2, Day 28 post vaccination</time_frame>
        <population>Secondary objective examines response in adjuvant and high dose recipients to A/Hong Kong (siat cell) virus in year 2, post vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination</title>
          <description>Microneutralization antibody titers to vaccine virus (A/Hong Kong (siat cell) among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2017-18</description>
          <population>Secondary objective examines response in adjuvant and high dose recipients to A/Hong Kong (siat cell) virus in year 2, post vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="55" upper_limit="96"/>
                    <measurement group_id="O2" value="95" lower_limit="71" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 28 days post vaccination 2017-18</description>
        <time_frame>Year 2, Day 28 post vaccination</time_frame>
        <population>This secondary objective aimed to look at subjects receiving standard dose vaccine in the previous season and one of 3 licensed vaccines in the 2017-18 season.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine +Adj</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Influenza Vaccine+HD</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Influenza Vaccine+Recomb</title>
            <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 28 days post vaccination 2017-18</description>
          <population>This secondary objective aimed to look at subjects receiving standard dose vaccine in the previous season and one of 3 licensed vaccines in the 2017-18 season.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="24" upper_limit="81"/>
                    <measurement group_id="O2" value="86" lower_limit="48" upper_limit="154"/>
                    <measurement group_id="O3" value="126" lower_limit="68" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="72" upper_limit="220"/>
                    <measurement group_id="O2" value="163" lower_limit="84" upper_limit="317"/>
                    <measurement group_id="O3" value="174" lower_limit="97" upper_limit="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="21" upper_limit="57"/>
                    <measurement group_id="O2" value="83" lower_limit="42" upper_limit="164"/>
                    <measurement group_id="O3" value="53" lower_limit="30" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination</title>
        <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 182 days post vaccination 2017-18</description>
        <time_frame>Year 2, Day 182 post vaccination</time_frame>
        <population>This secondary objective aimed to look at subjects receiving standard dose vaccine in the previous season and one of 3 licensed vaccines in the 2017-18 season.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine +Adj</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Influenza Vaccine+HD</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Influenza Vaccine+Recomb</title>
            <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination</title>
          <description>Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 182 days post vaccination 2017-18</description>
          <population>This secondary objective aimed to look at subjects receiving standard dose vaccine in the previous season and one of 3 licensed vaccines in the 2017-18 season.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="15" upper_limit="45"/>
                    <measurement group_id="O2" value="33" lower_limit="17" upper_limit="66"/>
                    <measurement group_id="O3" value="75" lower_limit="41" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="55" upper_limit="164"/>
                    <measurement group_id="O2" value="122" lower_limit="67" upper_limit="222"/>
                    <measurement group_id="O3" value="135" lower_limit="75" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="16" upper_limit="41"/>
                    <measurement group_id="O2" value="47" lower_limit="26" upper_limit="86"/>
                    <measurement group_id="O3" value="33" lower_limit="19" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination</title>
        <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 28 days after vaccination, 2017-18</description>
        <time_frame>Year 2, Day 28 post vaccination</time_frame>
        <population>This secondary objective selects individuals receiving high dose or adjuvanted vaccine in year 2 of the study and compares immune response by vaccine received in the prior season.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvant Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Influenza Vaccine +Adj</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O4">
            <title>Standard Dose Influenza Vaccine+HD</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination</title>
          <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 28 days after vaccination, 2017-18</description>
          <population>This secondary objective selects individuals receiving high dose or adjuvanted vaccine in year 2 of the study and compares immune response by vaccine received in the prior season.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="74" upper_limit="139"/>
                    <measurement group_id="O2" value="83" lower_limit="64" upper_limit="107"/>
                    <measurement group_id="O3" value="44" lower_limit="24" upper_limit="81"/>
                    <measurement group_id="O4" value="86" lower_limit="48" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="123" upper_limit="203"/>
                    <measurement group_id="O2" value="158" lower_limit="114" upper_limit="220"/>
                    <measurement group_id="O3" value="126" lower_limit="72" upper_limit="220"/>
                    <measurement group_id="O4" value="163" lower_limit="84" upper_limit="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="33" upper_limit="61"/>
                    <measurement group_id="O2" value="63" lower_limit="46" upper_limit="87"/>
                    <measurement group_id="O3" value="35" lower_limit="21" upper_limit="57"/>
                    <measurement group_id="O4" value="83" lower_limit="42" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination</title>
        <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 182 days after vaccination, 2017-18</description>
        <time_frame>Year 2, Day 182 post vaccination</time_frame>
        <population>This secondary objective selects individuals receiving high dose or adjuvanted vaccine in year 2 of the study and compares immune response by vaccine received in the prior season.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvant Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O2">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Influenza Vaccine +Adj</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O4">
            <title>Standard Dose Influenza Vaccine+HD</title>
            <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
        </group_list>
        <measure>
          <title>HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination</title>
          <description>Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 182 days after vaccination, 2017-18</description>
          <population>This secondary objective selects individuals receiving high dose or adjuvanted vaccine in year 2 of the study and compares immune response by vaccine received in the prior season.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1/Michigan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="32" upper_limit="61"/>
                    <measurement group_id="O2" value="46" lower_limit="35" upper_limit="51"/>
                    <measurement group_id="O3" value="26" lower_limit="15" upper_limit="45"/>
                    <measurement group_id="O4" value="33" lower_limit="17" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3/Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="93" upper_limit="165"/>
                    <measurement group_id="O2" value="101" lower_limit="74" upper_limit="138"/>
                    <measurement group_id="O3" value="95" lower_limit="55" upper_limit="164"/>
                    <measurement group_id="O4" value="122" lower_limit="67" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane(Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="O2" value="44" lower_limit="31" upper_limit="61"/>
                    <measurement group_id="O3" value="26" lower_limit="16" upper_limit="41"/>
                    <measurement group_id="O4" value="47" lower_limit="26" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vaccine Failure, Year 1</title>
        <description>Number of Participants with Vaccine Failure in Year 1 by vaccine type</description>
        <time_frame>Year 1, Post season</time_frame>
        <population>Results of influenza surveillance after the first year examines individuals by the vaccine type received in Year 1.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group received High Dose vaccine in the first year of the study.</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group received adjuvanted vaccine in the first year of the study.</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Influenza Vaccine</title>
            <description>This group received standard dose in the first year of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine Failure, Year 1</title>
          <description>Number of Participants with Vaccine Failure in Year 1 by vaccine type</description>
          <population>Results of influenza surveillance after the first year examines individuals by the vaccine type received in Year 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3 Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vaccine Failure, Year 2</title>
        <description>Number of Participants with Vaccine Failure in Year 2 by two-year vaccine history</description>
        <time_frame>Year 2, Post season</time_frame>
        <population>Results of influenza surveillance after the second year examines individuals by groups based on the vaccine types received in both seasons.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Influenza Vaccine</title>
            <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O2">
            <title>Adjuvanted Influenza Vaccine</title>
            <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O3">
            <title>Standard+High Dose</title>
            <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and high dose influenza vaccination (0.5mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
          </group>
          <group group_id="O4">
            <title>Standard+Adjuvanted</title>
            <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
          </group>
          <group group_id="O5">
            <title>Standard+Recombinant</title>
            <description>This group will be administered standard influenza vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants.
Recombinant Influenza vaccine: Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine Failure, Year 2</title>
          <description>Number of Participants with Vaccine Failure in Year 2 by two-year vaccine history</description>
          <population>Results of influenza surveillance after the second year examines individuals by groups based on the vaccine types received in both seasons.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H3 positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Influenza Vaccine</title>
          <description>This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants</description>
        </group>
        <group group_id="E2">
          <title>Adjuvanted Influenza Vaccine</title>
          <description>This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants</description>
        </group>
        <group group_id="E3">
          <title>Standard Dose Influenza Vaccine+HD</title>
          <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
High Dose Influenza vaccine: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
        </group>
        <group group_id="E4">
          <title>Standard Dose Influenza Vaccine +Adj</title>
          <description>This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Adjuvanted Influenza vaccine: Licensed and FDA approved FluAd vaccine to be administered to study participants
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants</description>
        </group>
        <group group_id="E5">
          <title>Standard Dose Influenza Vaccine+Recomb</title>
          <description>This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
Standard Dose Influenza vaccine: Licensed and FDA approved Fluvirin vaccine to be administered to study participants
Recombinant Influenza vaccine: Licensed and FDA approved FluBlok vaccine to be administered to study participants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Marshfield Clinic Research Institute</organization>
      <phone>715-389-5088</phone>
      <email>king.jennifer@marshfieldresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

